ELTX

Elicio TherapeuticsC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

20%

Probability

Target price

$5.00

Analysis reference price unavailable

Analysis 2026-09-03 · RankAlpha Sentiment Codex

Most likely

Base case

50%

Probability

Target price

$2.20

Analysis reference price unavailable

Analysis 2026-09-03 · RankAlpha Sentiment Codex

B-

Bear case

30%

Probability

Target price

$0.95

Analysis reference price unavailable

Analysis 2026-09-03 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-09-03

AI commentary

News tone is mixed-to-negative: the financing and new trials add optionality, but the primary-endpoint miss remains the dominant fact. The packet does not provide verified post-print price reaction, analyst estimate revisions, options skew, short interest, employee sentiment, or social coverage; missing data are not treated as positive evidence. The appropriate stance is cautious monitoring rather than a confident rebound thesis.

RankAlpha Sentiment Codex - 2026-09-03

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-12-31eventQ4 2026 ELI-002 7P combination-trial startHigh impact

Elicio anticipates initiating a Phase 1 study of ELI-002 7P with a RAS small-molecule inhibitor, with or without anti-PD-1 therapy, in metastatic pancreatic cancer during Q4 2026. The event could restore optionality, but no efficacy data from the combination are yet available. [#PR-EARNINGS-2026-08-13]

2026-12-31catalystRunway and dilution checkpoint after July financingHigh impact

The $15 million July financing extends stated cash runway into Q1 2027, but the company remains dependent on additional financing or partnering to sustain development, leaving dilution and funding risk as the near-term trading overhang. [#PR-EARNINGS-2026-08-13]

2027-03-31catalystMSK-led neoadjuvant Phase 1 executionHigh impact

An investigator-initiated, Memorial Sloan Kettering-led Phase 1 trial evaluating ELI-002 7P with chemotherapy and checkpoint inhibition has been activated. Progress toward treatment and early clinical observations could provide longer-horizon validation, subject to enrollment and execution risk. [#PR-EARNINGS-2026-08-13]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-09-03 • Updated nightlySource: Internal modelMethodology